Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| bioAffinity Technologies, Inc.BIAF · Entity 8368 | Chief Sci. & Med. Officer, EVP | January 31, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
bioAffinity Technologies, Inc.
Report date January 31, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,228 |
Reported balance
After 2024-01-31 transaction · row 1
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 31,847 · Balance 46,228 F1: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 2, 2024 16:21 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 31,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004762 · ownership.xml · nonDerivative · entry 1 Rebel Vivienne I · CIK 0001947548 · Chief Sci. & Med. Officer, EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,228 F1 · shares: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. Read SEC document |
| November 17, 2022 Filed Nov 22, 2022 16:49 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock, par value $0.007 | 7,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-033370 · ownership.xml · nonDerivative · entry 1 Rebel Vivienne I · CIK 0001947548 · EVP, Chief Sci. & Med. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,381 F1 · kind: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date. F1 · shares: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.